{"id":"W2153935627","doi":"10.1093/jnci/djn134","title":"Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma","year":2008,"lang":"en","type":"review","venue":"JNCI Journal of the National Cancer Institute","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1664,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Center for Research Resources; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Clinical endpoint; Clinical trial; Surrogate endpoint; Clinical study design; Sorafenib; Oncology; Internal medicine; Population; Randomized controlled trial; Hepatocellular carcinoma; Liver function; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6514346438688952,"score_gpt":0.4969074105035567,"score_spread":0.1545272333653385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}